Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B

•This RCT-based prospective cohort study included 1,000 patients and lasted for 7 years.•Compared with ETV treatment, the combination of ETV + Biejia-Ruangan compound could further reduce the incidence of HCC.•Biejia-Ruangan compound in addition to ETV should be considered for patients with CHB and advanced fibrosis or cirrhosis.